Lincluden Management Ltd. Purchases New Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Lincluden Management Ltd. has acquired a new position in Thermo Fisher Scientific Inc. by purchasing 13,628 shares valued at approximately $5,526,000 during the 2nd quarter.
• A number of institutional investors have significantly increased their holdings in Thermo Fisher, with firms like Brighton Jones LLC and GAMMA Investing LLC boosting their positions by 28.9% and 22.0%, respectively.
• Thermo Fisher Scientific reported earnings of $5.36 per share, exceeding analysts' estimates, and has set a Q3 2025 guidance at 5.460-5.510 EPS.

Lincluden Management Ltd. acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 13,628 shares of the medical research company's stock, valued at approximately $5,526,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in TMO. Brighton Jones LLC boosted its position in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. GAMMA Investing LLC boosted its position in Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares in the last quarter. GPS Wealth Strategies Group LLC boosted its position in Thermo Fisher Scientific by 33.5% during the first quarter. GPS Wealth Strategies Group LLC now owns 363 shares of the medical research company's stock valued at $181,000 after purchasing an additional 91 shares in the last quarter. Finally, West Branch Capital LLC boosted its position in Thermo Fisher Scientific by 10.9% during the first quarter. West Branch Capital LLC now owns 3,008 shares of the medical research company's stock valued at $1,497,000 after purchasing an additional 296 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. William Blair assumed coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating on the stock. Scotiabank raised Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research report on Friday, July 11th. Robert W. Baird upped their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research report on Thursday, July 24th. Finally, Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research report on Wednesday. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $593.43.

Thermo Fisher Scientific Stock Down 1.8%

Shares of TMO stock opened at $524.95 on Friday. The stock's 50-day simple moving average is $488.68 and its 200-day simple moving average is $447.94. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market capitalization of $198.23 billion, a PE ratio of 30.36, a P/E/G ratio of 2.85 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 over the last ninety days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.